A Study Of The Efficacy And Safety Of Anidulafungin Vs. Fluconazole In The Treatment Of Patients With Candidemia And/Or Other Forms Of Invasive Candidiasis

• Status: Terminated
• Trial end date: 2011-11-01
• Target enrollment: 0
• Participant gender: All

Summary

In the treatment of patients with candidemia and/or other forms of invasive candidiasis , Anidulafungin is at least as effective and safe as Fluconazole.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Pfizer
• Treatments: Anidulafungin; Echinocandins; Fluconazole

Criteria

Inclusion Criteria:

• Presence of candidemia or invasive candidiasis.

• Presence of one or more of signs and symptoms of acute fungal infection.

Exclusion Criteria:

• Subjects who received greater than 48 hours of systemic antifungal treatment for the Candida infection for which they will be enrolled.

• Subjects with hypersensitivity to echinocandins or azole therapy or drug excipients.